Real-time Focus Areas
Loading...
Analysing your metrics
🩸 Latest Blood Work — May 24 2026
LifeLabs · Dr. Sanjeev Goel
Hemoglobin 133 g/L — Thal. minor
MCV 72 fL — Thal. minor
MCH 22.4 pg — Thal. minor
RDW 17.9% — Monitor trend
Neutrophils 1.9 — Borderline
Glucose 4.5 mmol/L
HbA1c 5.6%
Triglycerides 0.59 mmol/L
Total-T 25.0 nmol/L
Vit D 218 nmol/L
Today's Vitals
Trends
Resting Heart Rate
avg —
HRV (RMSSD)
avg —
SpO₂
avg —
Weight
—
Body Fat %
—
Sleep Duration
avg —
Last Night's Sleep Stages
Sleep Duration — 30 Days
Sleep Stage Breakdown — 30 Days
Deep Sleep → HGH Efficacy Proxy — 30 Days
Loading…
Deep Sleep (min)
GH Pulse Opportunity threshold (75 min)
HGH Protocol Context (0.4mg daily)
~70% of nocturnal GH pulses coincide with slow-wave (deep) sleep. Exogenous HGH amplifies this pattern — but nights with less than ~75 min of deep sleep reduce the window for optimal GH pulse alignment. Nights below threshold are shown in red. Consistent deep sleep above 90 min represents the highest-ROI window for your HGH dose.
Resting Heart Rate — 30 Days
HRV (RMSSD) — 30 Days
SpO₂ — 30 Days
Today's Heart Rate
Heart Rate Zones — 7 Days
Last 7 sessions
VO2 Max — Trend
—
Respiratory Rate — 30 Days
avg —
Zone 2 + VO₂ Max Progression Engine
🎯 Your MAF Zone 2 HR Band
Calculating from current RHR…
MAF Method: 180 − age (38) = 142 bpm ceiling · Lower bound: 122 bpm · Target: 122–142 bpm during Zone 2 sessions
VO₂ Max
—
mL/kg/min
Loading percentile…
Weekly Zone 2 Dose
~60
min / week
Target: 150 min/wk
Sessions / Week
2×
30 min each
2.5× below target
VO₂ Percentile
—
for age 38 male
—
Weekly Zone 2 Dose
~60 min vs 150 min target
0150 min target (Mandsager longevity threshold)180+
VO₂ Max Trend — Percentile Benchmarked
Loading…
⚠️ Zone 2 Dose Gap
At 2× 30 min/week (≈60 min), you are 2.5× below the Mandsager et al. mortality-benefit threshold of 150 min/week.
The all-cause mortality curve shows the steepest benefit from 0→150 min/week — you are in the highest-yield improvement zone.
Each additional Zone 2 session has outsized longevity ROI compared to more resistance training.
Suggested: add 1–2 more 30-min sessions or extend existing sessions to 45–60 min.
Daily Steps — Last 7 Days
avg —
Active Zone Minutes — Last 7 Days
—
Recent Exercise Sessions
My Protocol
16 active interventions across 5 biological systems
Hormones
5
Foundation
Mitochondrial
3
Energy
Training
3
Strength + Cardio
Neural
3
Mind + Breath
Recovery
2
Sauna + Sleep
Protocol Efficacy — Blood Work Confirmation
Each intervention mapped to its target biomarkers from your May 24, 2026 LifeLabs panel. Green = confirmed working. Yellow = monitor. Grey = not yet tested.
💉
Retatrutide (6mg weekly)
Confirmed ✓
HbA1c
5.6%
Glucose
4.5 mmol/L
Insulin
26 pmol/L
Triglycerides
0.59 mmol/L
LDL
3.06 mmol/L
Metabolic panel is a clean sweep — HOMA-IR estimated at ~0.5, insulin sensitivity is optimal. LDL is within range but track at next draw as Retatrutide can modestly influence cholesterol. As fat loss progresses, triglycerides may drop further. Gap: liver enzymes (ALT 19, AST 23, GGT 16 — all good) should be monitored every 4–8 weeks for the first 6 months of Retatrutide due to glucagon-driven hepatic effects.
🏋️
Testosterone / TRT (0.4ml weekly)
Confirmed ✓
Total-T
25.0 nmol/L
Free-T
490 pmol/L
Estradiol
112 pmol/L
SHBG
Not tested
Dose is well-calibrated — Total-T near top of range without going supraphysiological. T:E2 ratio is healthy with no aromatization concerns. SHBG is not in current panel — it's needed to accurately interpret Free-T and optimize dose efficiency. Add to next draw. As Retatrutide-driven fat loss progresses, reduced peripheral aromatization will likely lower E2 — watch this at next panel.
🌱
Human Growth Hormone (0.4mg daily)
Critical Gap
IGF-1
Not tested
DHEA-S
5.1 umol/L
Neutrophils
1.9 ×10⁹/L
IGF-1 is absent from your current panel — this is the primary pharmacodynamic readout for HGH therapy and the single most important missing marker in your stack. Without it there is zero visibility into whether the 0.4mg dose is achieving therapeutic IGF-1 levels or overshooting. HGH + DHEA both upregulate IGF-1 signaling — combined, they could produce supra-physiologic levels. Neutrophils at 1.9 are borderline low and may be modulated by HGH-driven G-CSF effects; this should improve longitudinally as HGH therapy matures.
🧬
KLOW Peptide (10mg weekly)
Biomarkers Pending
hsCRP
Not tested
IL-6 / TNF-α
Not tested
Triglycerides
0.59 mmol/L
KLOW's FOXO3a activation and GHK-Cu-mediated NF-κB suppression require 4–12 weeks of consistent use before detectable biomarker changes appear. The inflammatory pathway markers (hsCRP, IL-6, TNF-α) are not in your current panel — add hsCRP to the next draw as a first-line inflammatory proxy. Triglycerides at 0.59 mmol/L is an indirect positive signal. Wearable HRV trend is the most accessible real-time proxy.
🐟
Omega-3 (2,500mg daily)
Confirmed ✓
Triglycerides
0.59 mmol/L
HDL
1.51 mmol/L
Mercury (Blood)
19 nmol/L
TG at 0.59 mmol/L is in the top ~5% of the population — a direct reflection of Omega-3 + Retatrutide + low-carb diet working together. Mercury at 19 nmol/L (ref <29) confirms the high daily dose is not accumulating to unsafe levels. Lp(a) at 33 nmol/L is in the low-risk zone — Omega-3s do not reduce Lp(a) but the overall cardioprotective picture is strong.
🌙
Magnesium Glycinate (300mg nightly)
Live Data Proxy
HRV (live)
Loading…
Deep Sleep (live)
Loading…
Serum magnesium is a poor marker for intracellular status — wearable HRV and deep sleep duration are the best accessible proxies for magnesium-mediated parasympathetic tone. Published research confirms 300mg+ magnesium glycinate elevates HRV via vagal tone enhancement. Your live HRV and last night's deep sleep are shown above — they update with each dashboard refresh.
RetatrutidePeptide
6mg weekly injection
Improves incretin signaling, insulin sensitivity, appetite regulation, and fat oxidation without forcing caloric stress.
✓ Controlled fat mass with preserved metabolic rate.
KLOW PeptidePeptide
10mg weekly injection
Supports fat oxidation signaling without sympathetic activation, preserving nervous system tone.
✓ Fat loss alongside stable resting heart rate.
Testosterone (TRT)Hormone
0.4ml weekly injection
Preserves lean mass, bone density, insulin sensitivity, and recovery capacity.
✓ Stable lean and skeletal muscle mass.
Human Growth HormoneHormone
0.4mg weekly injection
Supports connective tissue repair, collagen synthesis, and sleep dependent recovery.
✓ Structural tissue quality remains strong.
DHEAHormone
25mg daily
Buffers stress mediated hormonal suppression and supports neurosteroid balance.
✓ Stable metabolic age and autonomic tone.
CreatineSupplement
5g daily
Buffers ATP demand for muscular and cognitive output.
✓ Sustained training capacity.
IM8 Daily Essentials + Ultimate LongevitySupplement
1 pack of each daily
Supports micronutrient sufficiency and cellular resilience.
✓ Consistent energy and recovery.
Omega-3 Fatty AcidsSupplement
2,500mg daily
Supports membrane health and inflammation control.
✓ Low visceral risk profile.
Magnesium GlycinateSupplement
300mg nightly
Enhances sleep quality, parasympathetic dominance, and glymphatic clearance.
✓ Recovery and metabolic markers remain stable.
Melatonin (Travel)Supplement
5–10mg when traveling
Resets circadian rhythm during time zone shifts to preserve sleep quality and hormonal timing.
✓ Maintained recovery metrics during travel.
Morning Breathing PracticeMindfulness
10 minutes daily
Activates parasympathetic tone, improves CO2 tolerance, and sets autonomic balance for the day.
✓ Stable resting heart rate and recovery profile.
Morning MeditationMindfulness
15 minutes daily
Reduces baseline stress tone, improves cognitive clarity, and reinforces nervous system regulation.
✓ Preserved autonomic balance and metabolic stability.
Evening Breathing & Wind DownMindfulness
10–15 minutes nightly
Reinforces parasympathetic dominance and prepares the nervous system for sleep.
✓ Sleep quality and recovery scores remain stable.
Red Light TherapyRecovery
10 minutes daily
Supports mitochondrial signaling, circadian entrainment, and tissue repair.
✓ Strong cellular health and metabolic efficiency.
Vibration PlateRecovery
1x/week · 5 minutes
Induces neuromuscular efficiency and lymphatic circulation.
✓ Balanced recovery indicators.
SaunaRecovery
Biweekly · 20 min/session
Induces heat shock proteins, cardiovascular conditioning, and parasympathetic recovery.
✓ Balanced recovery indicators.
Resistance TrainingTraining
5 days/week · 30 min/session
Maintains muscle as an endocrine organ and supports glucose disposal.
✓ Preserved skeletal muscle mass.
Zone 2 CardioTraining
2 sessions/week · 30 min each
Drives mitochondrial biogenesis with low sympathetic load.
✓ Efficient resting heart rate.
Protocol Interaction Intelligence
Cross-intervention signals specific to your stack — time-sensitive flags, synergies, and monitoring priorities derived from your exact combination of peptides, hormones, and biometrics.
HGH + DHEA → IGF-1 Amplification Risk
Both HGH and DHEA independently upregulate IGF-1 / IGF-1R signaling. Combined at your doses (HGH 0.4mg daily + DHEA 25mg daily), there is potential for supra-physiologic IGF-1 levels — associated with increased cellular proliferation signaling if sustained. Without an IGF-1 lab measurement, this interaction is completely unmonitored. This is the highest-priority monitoring gap in your entire protocol.
→ Action: Add IGF-1 to next blood draw immediately. Target range for longevity: 150–250 ng/mL.
Retatrutide Fat Loss → E2 Decline (Time-Sensitive)
As Retatrutide-driven fat loss progresses, peripheral aromatization decreases — meaning your estradiol (currently 112 pmol/L, controlled) will trend downward over the coming months. At your TRT dose, a drop in E2 below ~70 pmol/L can impair joint recovery, libido, sleep quality, and bone density. This is not a current problem — it's a predictable future interaction that requires monitoring.
→ Action: Retest E2 at next blood draw (ideally within 8–10 weeks). If E2 drops below 80 pmol/L, discuss aromatase timing with your physician.
TRT → Erythropoiesis Watch (HCT / Hemoglobin)
TRT stimulates erythropoiesis — raising hematocrit and hemoglobin. In your case, thalassemia minor creates an offset effect (lower baseline Hgb 133 g/L), which partially masks TRT-driven polycythemia risk. However, long-term TRT use can still elevate HCT above safe thresholds (>52%). Your current Hgb of 133 is low-normal — this gap provides some protective buffer but should be tracked longitudinally.
→ Action: Ensure CBC (including HCT/Hgb) is included in every blood draw while on TRT. Track trend across panels.
Magnesium Glycinate → HRV Validation Opportunity
300mg+ magnesium glycinate nightly has documented HRV-elevating effects via enhanced vagal tone and NMDA receptor modulation. Your wearable HRV data provides a direct real-time proxy for this intervention's efficacy without needing a blood draw. A rising HRV trend correlated with consistent Mg use is a positive confirmation. If HRV remains suppressed despite Mg adherence, consider dose optimization (up to 400mg) or timing shift (earlier in the evening).
→ Track: Check your 30-day HRV trend on the Heart tab. Stable or rising HRV = Mg working. Flat or declining = consider dose review.
Retatrutide + Omega-3 → Synergistic Lipid Optimization
Retatrutide's GLP-1/GIP/glucagon tri-agonism reduces hepatic VLDL secretion; Omega-3 independently suppresses triglyceride synthesis via PPAR-α. The combination is producing exceptional results — TG at 0.59 mmol/L is genuinely elite and reflects both mechanisms working together. This synergy also improves HDL particle quality, reducing cardiovascular risk beyond what either agent achieves alone.
→ Confirmed: No action needed. Maintain both. This is one of the strongest protocol synergies in your stack.
TRT + Creatine + Resistance Training → Anabolic Synergy
TRT elevates androgen receptor density and satellite cell activation; creatine (5g/day) buffers ATP demand and amplifies mTOR signaling; resistance training 5×/week provides the mechanical stimulus. These three interact multiplicatively — each amplifies the effect of the others. Your lean mass preservation under Retatrutide (which would otherwise cause some muscle loss via caloric restriction mechanisms) is likely attributable to this triple combination holding the anabolic floor.
→ Confirmed: Continue. Ensure protein intake is ≥1.6g/kg bodyweight to fully exploit this synergy.
🧬 Peptide Recommendations
Data-driven peptide suggestions based on your live metrics. Status updates automatically as your RHR, HRV, deep sleep, and body composition data changes.
Loading recommendations…
🧬
Thalassemia Minor — Active Context
Low Hemoglobin (133), MCV (72), MCH (22.4) are expected findings — not iron deficiency. Ferritin 228 confirms iron stores are excellent. RDW elevation and false-high HbA1c are also characteristic of thalassemia minor.
⚑ Next panel: add IGF-1 to validate HGH protocol · monitor neutrophils trend · consider hemoglobin fractionation per pathologist
Blood Work Analysis
LifeLabs · May 24, 2026 · Requesting: Dr. Sanjeev Goel
⚠ Thalassemia Minor Context
Low MCV, MCH, and mildly low hemoglobin are expected findings in thalassemia minor and do not indicate iron deficiency. RDW elevation and RBC morphology changes (elliptocytes, microcytosis) are also characteristic. These flags are noted below but are not clinically concerning given your known status.
Metabolic
✓
All optimal
Cardiovascular
✓
Excellent
Hormones
✓
All in range
CBC
⚑
Thal. minor
Kidney/Liver
✓
Normal
Toxicology
✓
Clear
Complete Blood Count
Hemoglobin Thal. minor
133 g/L
Ref: 135–175 g/L · Flagged L by lab
Mildly below range but expected in thalassemia minor. Not indicative of iron deficiency — ferritin is 228 ug/L (well stocked).
WBC
5.5 ×10⁹/L
Ref: 4.0–11.0 · Normal
Healthy immune baseline. No signs of infection or immune suppression.
RBC
5.93 ×10¹²/L
Ref: 4.50–6.00 · Normal
High-normal RBC is classic in thalassemia minor — body compensates for smaller cells by making more of them.
MCV Thal. minor
72 fL
Ref: 80–100 fL · Flagged L
Small red cells are the hallmark of thalassemia minor. Not iron-deficiency — ferritin rules that out.
MCH Thal. minor
22.4 pg
Ref: 27.5–33.0 pg · Flagged L
Low MCH is expected — each small cell carries less hemoglobin. Consistent with thalassemia minor pattern.
MCHC
314 g/L
Ref: 305–360 · Normal
Normal MCHC alongside low MCV/MCH further confirms thalassemia minor rather than iron deficiency anemia.
RDW
17.9 %
Ref: 11.5–14.5% · Flagged H
Elevated RDW indicates variation in red cell size. Common in thalassemia. Worth monitoring trend — no urgent action needed.
Platelets
309 ×10⁹/L
Ref: 150–400 · Normal
Healthy platelet count. No clotting or bleeding risk concerns.
Neutrophils
1.9 ×10⁹/L
Ref: 2.0–7.5 · Borderline L
Just below the lower limit. Mild relative neutropenia can occur with TRT and peptide protocols. Monitor at next blood draw.
Lymphocytes
3.1 ×10⁹/L
Ref: 1.0–3.5 · Normal
Strong adaptive immune function.
Metabolic & Glucose
Fasting Glucose
4.5 mmol/L
Ref: 3.6–6.0 · Optimal
Excellent fasting glucose. Well within normal range — Retatrutide and low-carb protocol are working.
HbA1c
5.6 %
Ref: <6.0% · At-risk threshold 5.5%
Technically in the "at risk" range (5.5–5.9%) by Diabetes Canada guidelines. Note: HbA1c may read slightly higher than true value in thalassemia minor due to altered RBC turnover. Functionally excellent given fasting glucose of 4.5.
Fasting Insulin
26 pmol/L
Ref: 20–180 · Excellent
Very low fasting insulin indicates excellent insulin sensitivity. HOMA-IR is estimated at ~0.5 — optimal metabolic health.
Urate
249 umol/L
Ref: 230–480 · Normal
Normal uric acid. No gout risk. Omega-3 and hydration appear effective.
Cardiovascular & Lipids
Total Cholesterol
4.83 mmol/L
Ref: <5.20 · Normal
Well within range. Good overall cholesterol burden.
HDL Cholesterol
1.51 mmol/L
Ref: ≥1.00 · Good
Healthy HDL. Zone 2 cardio and Omega-3s are contributing to this result.
LDL Cholesterol
3.06 mmol/L
Ref: <3.50 · Normal
Within range. Chol/HDL ratio of 3.2 is excellent (risk threshold is >6.0).
Triglycerides
0.59 mmol/L
Ref: <1.70 (fasting) · Excellent
Exceptionally low triglycerides. This is a standout result — strong indicator of metabolic health and low visceral fat.
Lipoprotein(a)
33 nmol/L
Ref: <100 · Low risk
Low Lp(a) — a genetically-fixed cardiovascular risk marker. This is a strong result. Test only needed once in a lifetime.
Hormones & Endocrine
Testosterone (Total)
25.0 nmol/L
Ref: 8.4–28.8 · Excellent
High-normal testosterone. TRT protocol is well-calibrated — near top of range without going supraphysiological.
Testosterone (Free)
490 pmol/L
Ref: 196–636 · Good
Free testosterone is the biologically active fraction. Mid-range free T alongside high total T suggests healthy SHBG levels.
Estradiol
112 pmol/L
Ref: <162 · Normal
Well-controlled estradiol alongside high testosterone — good T:E2 ratio. No aromatization concerns at current TRT dose.
DHEA-S
5.1 umol/L
Ref: <15.0 · Normal
Within range. DHEA supplementation at 25mg/day is maintaining healthy levels without excess.
HGH (via IGF proxy)
—
Not directly tested
HGH effect best tracked via IGF-1 — consider adding to next panel to validate HGH protocol response.
TSH
1.04 mIU/L
Ref: 0.32–4.00 · Optimal
Excellent thyroid function. Low-normal TSH is associated with better metabolic rate and energy.
Cortisol (AM)
266 nmol/L
Ref: 80–535 · Normal
Collected at 09:35 AM. Mid-range morning cortisol — appropriate diurnal peak. Breathing and meditation practice appears to be moderating stress axis well.
Liver, Kidney & Nutrition
ALT
19 U/L
Ref: <50 · Excellent
Very low liver enzyme. No liver stress despite hormone protocol — hepatic health is strong.
AST
23 U/L
Ref: <35 · Normal
Normal AST. ALT/AST ratio is healthy — no signs of liver or muscle stress.
GGT
16 U/L
Ref: <65 · Excellent
Low GGT indicates minimal oxidative stress on the liver. Excellent result.
Creatinine
92 umol/L
Ref: 67–117 · Normal
Normal kidney filtration marker. Creatine supplementation not causing renal stress.
eGFR
91 mL/min
Ref: ≥60 · Normal
Good kidney function. Stage 2 CKD threshold is <60 — you're well above it.
Vitamin B12
532 pmol/L
Ref: >220 · Optimal
Excellent B12. IM8 supplement and diet are maintaining strong neurological and methylation support.
Ferritin
228 ug/L
Ref: 101–300 normal · Good
Important in context of thalassemia minor — confirms iron stores are healthy, not deficient. Rules out iron deficiency as cause of low hemoglobin/MCV.
Vitamin D
218.0 nmol/L
Ref: 75–250 · Optimal
Excellent Vitamin D. Near the top of optimal range — supports immune function, hormonal health, and bone density.
Albumin/Creatinine Ratio
1.1 mg/mmol
Ref: <3.0 · Normal
No albuminuria — kidney filtration barrier intact. Very low CKD progression risk.
Toxicology
Lead (Blood)
0.03 umol/L
Ref: <0.10 · Clear
Very low blood lead. No environmental or occupational heavy metal exposure concern.
Mercury (Blood)
19 nmol/L
Ref: <29 · Normal
Within range despite high Omega-3/fish intake. Mercury clearance is healthy.
🫀 Cardiovascular Longevity Risk Panel
📊
Lp(a) Risk Spectrum — EAS / NLA Guidelines
You: 33 nmol/L
75 nmol/L
125 nmol/L
◆ Low Risk (<75)
◆ Intermediate (75–125)
◆ High Risk (>125)
✓ Low-risk zone. Lp(a) is primarily genetic and non-modifiable. Because you cannot lower Lp(a) through lifestyle or most drugs, risk management pivots entirely to optimizing your modifiable co-variables: ApoB trajectory, inflammation (hsCRP), metabolic health, and blood pressure. Your current protocol addresses all of these — but ApoB and hsCRP are not yet measured.
ASCVD Protection Scorecard — Protocol Coverage
Zone 2 Cardio
2×/week 30 min — aerobic stress reduction
Retatrutide
TG 0.59 ✓ · Glucose 4.5 ✓ · LDL 3.06 watch
Omega-3 (2,500 mg/day)
TG exceptional · HDL 1.51 ✓ · Mercury safe
KLOW Peptide
GHK-Cu → NF-κB suppression · endothelial NO
Resistance Training
5×/week 30 min — insulin sensitivity, lean mass
Magnesium Glycinate
300 mg/night — parasympathetic tone, HRV
⚠️ Missing Measurements — ASCVD Blind Spots
ApoB — Not Measured
The most accurate atherogenic particle count available. LDL-C (3.06) may underestimate risk when ApoB is high despite low TG. Essential given Lp(a) 33 nmol/L background. Add to next draw — critical.
hsCRP — Not Measured
High-sensitivity CRP is the primary systemic inflammation marker and a key PhenoAge component. Validates KLOW's NF-κB pathway. Target <1.0 mg/L for longevity. Without it, your cardiovascular inflammatory burden is invisible.
LDL — Monitor Trend
LDL-C at 3.06 mmol/L is within normal range but sits above the longevity-optimal <2.6 mmol/L target. Retatrutide should trend this lower over 6–12 months. Track trajectory at next draw.
Weight — 90 Days
—
Body Fat % — 90 Days
—